Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
about
The role of the ALK receptor in cancer biologyBrigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomasTherapeutically Targetable ALK Mutations in LeukemiaPhosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma.Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma.Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.The role of anaplastic lymphoma kinase in pediatric cancers.Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma.The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.ALK in Neuroblastoma: Biological and Therapeutic Implications.
P2860
Q26738384-7DA62B16-5CDE-4A98-9056-5B8B48C4D2DCQ27853373-25285904-F4D0-406E-B3E9-07A442132AB5Q33897022-4899305C-527C-49D2-A4A9-9336ACADF98FQ34134105-CAC38AA0-C5E2-4C32-8B4B-6745C456B2E7Q35676273-B5FF7EDA-5AB3-4C9D-A4B5-B5EDC72342EEQ37480414-27B48C27-5A02-4F6B-B849-0E92253F65C1Q38700613-B8D77ACF-A052-4BC8-A95F-682E75EF246DQ38855176-E95665E7-40E4-4A14-AEEA-8D0D48819991Q38953705-E8E0733A-0BC6-4207-8556-CC2D218273C1Q41038822-ACFC319F-BE38-4383-988C-288790B9FD49Q41844175-98CA2195-A606-43FB-89DE-1CF0CB9EEB58Q42823847-FE63E02F-546A-49F9-8DE4-030413E2B28CQ47107337-23E9DA50-E936-45D9-AD22-21986997EAC3Q51734147-A1C8647C-DCCE-4F5C-A9ED-0C218E2C6434Q52324760-8425C980-3283-4A5D-A1CA-C1EF7F6C534C
P2860
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
@en
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
@nl
type
label
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
@en
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
@nl
prefLabel
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
@en
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
@nl
P2093
P2860
P356
P1433
P1476
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma
@en
P2093
R Nishimura
T Igarashi
P2860
P2888
P304
P356
10.1038/ONC.2011.616
P407
P577
2012-01-16T00:00:00Z